Introduction {#sec1}
============

It is estimated that there are 350 million people chronically infected by hepatitis B virus (HBV) in the world \[[@cit0001]\]. Most of these carriers are inactive in terms of viral replication or symptoms, but the risk of HBV reactivation is important in lymphoma patients receiving immunosuppressive chemotherapy, especially containing steroids and/or anti-CD-20 antibodies, that can reduce B cell numbers and antibody levels \[[@cit0002]\]. Huang *et al.* analyzed a group of lymphoma patients and resolved hepatitis B and they found that undetectable HBV viral load before chemotherapy did not confer reactivation-free status \[[@cit0003]\]. After rituximab-based therapy, the incidence of HBV reactivation in patients with lymphoma and resolved hepatitis B is reported up to 23.8% \[[@cit0004]\]. Thus, appropriate screening and prophylaxis strategies need to be implemented in high-risk populations. The results of multiple studies have demonstrated that antiviral prophylaxis interventions can reduce the risk of HBV reactivation \[[@cit0003]\]. Hence, appropriate identification of the population at risk of HBV reactivation remains crucial in order to reduce the incidence of this complication in lymphoma patients.

In 2015, the American Gastroenterology Association (AGA) published guidelines on the prevention of hepatitis B virus reactivation during immunosuppressive drug therapy. AGA defined the high-risk group as anticipated incidence of HBV reactivation in \> 10% of cases. This group includes: 1) HBsAg-positive/anti-HBc-positive or HBsAg-negative/anti-HBc-positive patients treated with B cell-depleting agents (for example rituximab, ofatumumab) and 2) HBsAg-positive/anti-HBc-positive patients treated with anthracycline derivatives (for example, doxorubicin, epirubicin) and 3) HBsAg-positive/anti-HBc-positive patients treated with moderate-dose (10--20 mg prednisone daily or equivalent) or high-dose (\> 20 mg prednisone daily or equivalent) corticosteroids daily for at least 4 weeks. For these high-risk patients the AGA recommended antiviral prophylaxis that should be continued at least 6 months after discontinuation of immunosuppressive therapy and at least 12 months for B-cell depleting agents \[[@cit0005]\]. In 2014, Seto *et al.* conducted a study in lymphoma patients HBsAg-negative, anti-HBc-positive with undetectable serum HBV DNA (\< 10 IU/ml) treated with rituximab-based regimens, demonstrating that a high rate of HBV reactivation was observed in this population, with the risk of reactivation significantly higher in anti-HBs-negative patients. Periodic HBV DNA monitoring was an effective strategy in preventing HBV-related complications \[[@cit0006]\].

The aim the study was to: (1) establish the prevalence of HBs Ag and anti-HBc serologic positive results in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia in Poland before anti-CD20 therapy initiation, (2) to assess the frequency of insufficient HBV screening, (3) to assess the association between inadequate HBV screening and diagnosis according to the WHO classification and age or gender.

Material and methods {#sec2}
====================

We retrospectively collected data in 4 hematology or oncology centers cooperating within the Polish Lymphoma Research Group from 805 patients diagnosed with non-Hodgkin lymphoma and chronic lymphocytic leukemia treated in 2016--2018, with a median age of 65. Most of the patients (over 90%) were treated with rituximab containing regimens. Data were collected anonymously and consisted of demographic data such as age, gender, ethnicity, WHO diagnosis, and laboratory results of HBsAg, anti-HBc, and anti-HBs blood test if available.

For the purpose of analysis we categorized four sub-groups: 1) diagnoses of aggressive and transformed lymphoma (including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, transformed indolent lymphomas into DLBCL), 2) chronic lymphocytic leukemia, 3) indolent lymphoma (including follicular lymphoma, plasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma) and 4) other (including mantle cell lymphoma, nasal T/NK-cell lymphoma).

Statistical analysis {#sec2.1}
--------------------

The nominal data were provided as absolute numbers and/or percent values. Making use of cross tabulations, the distribution of observations was presented in terms of several features simultaneously. For continuous variables the median and interquartile range (IQR) were calculated with the arithmetic mean and standard deviation (SD). The analysis of factors influencing non-performance of the complete examinations was assessed by means of univariate and multivariate logistic regression. The variables which turned out to be significant in univariate comparisons (*p* \< 0.1) were included in the multivariate model. Results were considered statistically significant for *p* \< 0.05. Statistical analyses were performed by means of the Statistica 12.0 (StatSoft, Poland) program.

Results {#sec3}
=======

Eight hundred and five Caucasian patients with a median age of 65 years (56--73, IQR = 8.5), 100% of Caucasian ethnicity, 378 (47%) female and 427 (53%) male subjects were enrolled. Diagnoses according to the WHO classification were distributed as in [Table I](#t0001){ref-type="table"}.

###### 

Diagnosis according to WHO classification

  WHO diagnosis                                               Number of patients (%) *N* = 805
  ----------------------------------------------------------- ----------------------------------
  Diffuse large B-cell lymphoma                               265 (32.9)
  Follicular lymphoma                                         68 (8.4)
  Nodal marginal-zone lymphoma                                33 (4.1)
  MALT lymphoma                                               15 (1.9)
  Mantle cell lymphoma                                        80 (9.9)
  Small lymphocytic lymphoma                                  34 (4.2)
  Waldenstrom macroglobulinemia/ lymphoplasmacytic lymphoma   19 (2.4)
  Chronic lymphocytic leukemia                                199 (24.7)
  Burkitt lymphoma                                            6 (0.8)
  DLBCL/HL                                                    6 (0.8)
  DLBCL/BL                                                    12 (1.6)
  FL/DLBCL                                                    10 (1.2)
  Other                                                       9 (1.1)
  CLL/DLBCL                                                   4 (0.5)
  Splenic marginal lymphoma                                   21 (2.6)
  Primary mediastinal large B-cell lymphoma                   22 (2.7)
  MZL/DLBCL                                                   2 (0.2)

DLBCL -- diffuse large B-cell lymphoma, MALT -- mucosa associated lymphoid tissue, DLBCL/HL -- B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma, DLBCL/BL -- B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma, FL/DLBCL -- DLBCL transformed from follicular lymphoma, CLL/DLBCL -- DLBCL transformed from chronic lymphocytic leukemia, MZL/DLBCL -- DLBCL transformed from marginal zone lymphoma.

We found a positive result of HBsAg in 13 (1.16%) patients and a negative result in 633 (78.64%) patients. The test was not done in 159 (19.75%) patients. Among patients with negative HBsAg the anti-HBc result was positive in 52 (8.22%) patients, negative in 303 (47.87%) patients and not done in 278 patients.

Logistic regression was further performed to study the relationship between the results of specific tests and chosen patients' characteristics. We were not able to identify an association between positive HBsAg result and any of the following factors: WHO diagnosis, gender or age ([Table II](#t0002){ref-type="table"}). Similarly, in the group of HBsAg negative and anti-HBc positive patients we did not find an association between the above-mentioned factors and the positive results. There was also no association between the lack of anti-HBc testing in HBsAg negative patients and the WHO diagnosis, gender or age ([Table III](#t0003){ref-type="table"}).

###### 

Risk of positive HBsAg result depending on analyzed factors -- results of univariate logistic regression

  Factor                         Odds ratio                            95% confidence interval   *P*-value      
  ------------------------------ ------------------------------------- ------------------------- -------------- -------
  WHO                            Aggressive and transformed lymphoma   1.185                     0.516--2.724   0.689
  Chronic lymphocytic leukemia   0.635                                 0.2--2.017                0.441          
  Indolent lymphoma              0.993                                 0.362--2.721              0.989          
  Other (5, 9, 13)               1.338                                 0.419--4.271              0.623          
  Gender                         Female                                0.838                     0.477--1.471   0.538
  Male                           1.193                                 0.68--2.1                                
  Age                                                                  0.986                     0.951--1.024   0.469

Result statistically significant for p \< 0.05.

###### 

Determination of positive anti-HBc result in patients with a negative HBsAg test depending on analyzed factors -- results of univariate logistic regression

  Factor                         Odds ratio                            95% confidence interval   *P*-value      
  ------------------------------ ------------------------------------- ------------------------- -------------- -------
  WHO                            Aggressive and transformed lymphoma   1.082                     0.688--1.702   0.731
  Chronic lymphocytic leukemia   0.894                                 0.52--1.536               0.685          
  Indolent lymphoma              1.272                                 0.774--2.01               0.343          
  Other                          0.813                                 0.396--1.667              0.571          
  Gender                         Female                                0.989                     0.74--1.307    0.908
  Male                           1.017                                 1.77--1.35                               
  Age                                                                  1.021                     0.998--1.043   0.069

Result statistically significant for p \< 0.05.

Then, we found that in 136 out of 805 (16.9%) patients no diagnostics tests were performed before therapy initiation. We then analyzed using logistic regression whether the lack of basic HBV infection screening result was associated with one of the above-mentioned factors. We found that age was significantly associated (*p* = 0.0002) with the lack of HBV infection screening, showing that each year of a patient's age increased the risk of lack of screening by 3%. Additionally, we found that the risk of lack of HBV infection screening is significantly (*p* = 0.024) higher (by 49%) in patients with CLL when compared to other WHO diagnosis subgroups. The results are presented in [Table IV](#t0004){ref-type="table"}.

###### 

Determination of chance to perform proper minimal HBV screening (HBsAg and anti-HBc) depending on analyzed factors -- results of univariate logistic regression

  Factor                         Odds ratio                            95% confidence interval   *P*-value                                
  ------------------------------ ------------------------------------- ------------------------- ---------------------------------------- -----------------------------------------
  WHO                            Aggressive and transformed lymphoma   0.760                     0.557--1.036                             0.083
  Chronic lymphocytic leukemia   1.495                                 1.056--2.118              0.024[\*](#tf4-1){ref-type="table-fn"}   
  Indolent lymphoma              0.912                                 0.636--1.308              0.617                                    
  Other                          0.965                                 0.604--1.542              0.881                                    
  Gender                         Female                                0.96                      0.790--1.167                             0.680
  Male                           1.042                                 0.857--1.267                                                       
  Age                                                                  1.03                      1.014-1.046                              0.0002[\*](#tf4-1){ref-type="table-fn"}

Result statistically significant for p \< 0.05.

Discussion {#sec4}
==========

Identification of patients with HBV infection is the most important step in preventing HBV reactivation as a result of anticancer therapies in lymphoma patients with special attention to those initiating immunosuppressive regimens with anti-CD20 monoclonal antibodies.

In this study, we analyzed a cohort of lymphoma and CLL patients undergoing systemic therapy, including anti-CD20 monoclonal antibodies in 90% of cases, and assessed screening for HBV infection. The main findings were that the overall frequency of testing for screening purposes was low, with 16.9% of the patients not being tested at all for HBV before initiation of therapy and an additional 34.5% of patients in whom screening was limited to a negative HBsAg result. Thus, 51.4% of non-Hodgkin lymphoma and CLL patients were not screened properly in order to minimize the risk of HBV reactivation during systemic treatment.

There is an important difference between guideline recommendations by the liver societies and those by the oncology professionals with regard to HBV screening prior to chemotherapy, but recommendations for lymphoma patients, especially starting anti-CD20 therapy, are clear and indicate the need of at least serologic screening for this entire population. As shown by Wi *et al*., the proportion of hematologic patients treated in Mayo Clinic in Rochester screened for HBV increased from 32.7% in 2006--2008 to 40.6% in 2009--2011 (*p* \< 0.01) \[[@cit0007]\]. Thus, our results show that only 48.6% of lymphoma and CLL patients treated during 2016--2018 in Poland were screened properly for HBV reactivation risk, which is in accordance with the results obtained in the Mayo Clinic. In our study gender was not a significant risk factor for insufficient HBV screening, while in the Mayo Clinic group male patients were more likely to have HBV screening. We found that age is significantly associated with the lack of HBV infection screening, which is consistent with the results obtained by Wi *et al.* \[[@cit0007]\]. In 2018, an Australian group conducted a study to determine: the adherence to the local protocol for HBV screening; the HBV infection prevalence in patients receiving rituximab; and outcomes of patients at risk of HBV reactivation. Adherence was assessed by documentation of both HBsAg and HBcAb prior to rituximab initiation. Two hundred and nine (47.7%) failed to receive appropriate HBV screening, 86 (19.6%) had neither HBsAg nor HBcAb performed, and 119 (27.2%) had only HBsAg performed \[[@cit0008]\]. These results are consistent with our observations, showing that insufficient HBV screening in lymphoma patients is a global problem requiring probably generalized educational efforts in the oncohematologic community.

In our analysis, in the HBsAg negative subgroup of 633 patients, we found an anti-HBc positive result in 8.22% of these patients, anti-HBc negative in 47.87% of patients and not done in 43.91% of patients. As shown in a meta-analysis published in 2017 \[[@cit0009]\], including a total of 1312 HBsAg-negative/HBc Ab-positive lymphoma patients treated with rituximab-containing chemotherapy, the HBV reactivation rate is 9.0% in retrospective and prospective studies, which provides evidence that potentially the risk of HBV reactivation in HBsAg-negative/HBc Ab-positive patients with rituximab treatment for lymphoma is substantial. This study is a rationale to intensify educational activities in the medical community treating lymphoma patients in order to incorporate the anti-HBc testing as a routine diagnostic procedure in HBsAg-negative lymphoma patients in daily clinical practice.

A total of 1962 patients with hematological malignancies were enrolled in a study in Taiwan. Of the 286 HBV carriers, 97 (33.9%) developed hepatitis B reactivation during or after chemotherapy. Of the 1676 patients with initial negative HBsAg counts, 41 (2.4%) experienced hepatitis B reactivation and reverse seroconversion of HBsAg, and lost their protective hepatitis B surface antibody (anti-HBs). Moreover, positive anti-HBc (*p* = 0.013, OR = 0.070, 95% CI: 0.009--0.571) was one of the independent risk factors of positive seroconversion of HBsAg in patients with hematological malignancy. This study provides a further rationale to support routine anti-HBc testing in all HBsAg negative patients with lymphoma. This study revealed that the incidence of HBV reactivation among the patients with different subtypes of hematological malignancy is similar \[[@cit0009], [@cit0010]\]. Thus, insufficient HBV infection screening in CLL patients in our study is not supported by scientific evidence.

Different screening strategies in oncology have different detection levels, as in colorectal cancer different endoscopic methods give an improved adenoma detection rate with implementation of novel technical methods \[[@cit0011]\]. Thus, more sensitive simple serologic detection of HBV infection could potentially decrease HBV reactivation risk in lymphoma and CLL patients.

In conclusion, in Polish lymphoma patients the incidence of positive HBsAg and/or anti-HBc results is consistent with the prevalence in the United States or Australia. The adherence to appropriate HBV screening guidelines in Polish centers is not sufficient but is similar to leading centers treating lymphoma, which provides further evidence to intensify educational strategies in the global oncohematologic medical community. Our study showed that we tend to omit proper HBV screening in elderly patients and in those with CLL more than non-Hodgkin lymphoma subtypes.
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